Profile data is unavailable for this security.
About the company
Lupin Limited is a global pharmaceutical company, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates in India and the United States across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti-Inflammatory Drug therapy segments and operates in the Anti-TB and Cephalosporins segments. Its generic formulations include Filgrastim, Peg filgrastim, Etanercept and Albuterol. Its diabetes brands include Gibtulio, Ajaduo, Gibtulio Met, ONDERO and ONDERO MET. Its other brands include AntaGolin, RyChol and others. Its Huminsulin range of products includes Insulin Human.
- Revenue in INR (TTM)227.08bn
- Net income in INR32.82bn
- Incorporated1983
- Employees21.87k
- LocationLupin Ltd3rd Floor,Kalpataru Inspire,, Off. Western ExpressMUMBAI 400055IndiaIND
- Phone+91 2 266402323
- Fax+91 2 266402051
- Websitehttps://www.lupin.com/
More ▼
Mergers & acquisitions
| Acquired company | LUPIN:NSI since announced | Transaction value |
|---|---|---|
| Eli Lilly & Co-Huminsulin | -13.35% | -- |
| Boehringer Ingelheim Gmbh-Ajaduo Trademark | -8.52% | -- |
| Boehringer Ingelheim Gmbh-Gibtulio Met Trademark | -8.52% | -- |
| Boehringer Ingelheim Gmbh-Gibtulio Trademark | -8.52% | -- |
Data delayed at least 15 minutes, as of Jul 18 2025 11:18 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals Ltd | 37.49bn | 9.28bn | 537.63bn | 3.11k | 58.22 | 27.55 | 54.07 | 14.34 | 54.51 | 54.51 | 220.41 | 115.19 | 0.9783 | 2.76 | 14.57 | 12,043,720.00 | 24.20 | 15.30 | 43.81 | 25.66 | 62.90 | 56.70 | 24.74 | 16.77 | 1.54 | 845.38 | 0.0051 | 137.07 | 8.56 | 3.06 | 57.23 | 53.14 | -31.03 | 16.00 |
| Alkem Laboratories Ltd | 129.65bn | 21.65bn | 600.06bn | 17.28k | 27.71 | 5.01 | 23.33 | 4.63 | 181.11 | 181.11 | 1,084.23 | 1,002.37 | 0.7795 | 1.67 | 5.46 | -- | 13.32 | 12.12 | 18.12 | 17.53 | 63.25 | 60.21 | 17.09 | 14.69 | 2.02 | 17.62 | 0.10 | 25.45 | 2.34 | 9.21 | 20.59 | 13.95 | 13.22 | 12.47 |
| Glenmark Pharmaceuticals Ltd | 133.22bn | 10.47bn | 628.38bn | 14.99k | 60.02 | 7.10 | 40.99 | 4.72 | 37.10 | 37.10 | 468.57 | 313.60 | 0.8762 | 1.57 | 5.12 | -- | 6.89 | 1.33 | 11.25 | 1.92 | 67.32 | 61.04 | 7.86 | 1.82 | 1.05 | 9.01 | 0.2184 | 39.62 | 12.77 | 4.60 | 155.14 | 6.18 | -4.24 | 0.00 |
| Aurobindo Pharma Ltd | 317.24bn | 34.86bn | 670.36bn | 8.80k | 19.30 | 2.05 | 13.06 | 2.11 | 59.81 | 59.81 | 544.32 | 562.21 | 0.6689 | 1.28 | 6.01 | -- | 7.34 | 8.62 | 10.25 | 12.13 | 58.94 | 54.51 | 10.98 | 12.38 | 1.13 | 9.69 | 0.202 | -- | 9.39 | 6.55 | 9.86 | 4.15 | 11.98 | -- |
| Abbott India Ltd | 64.09bn | 14.14bn | 725.98bn | 3.81k | 51.33 | 17.15 | 48.85 | 11.33 | 665.62 | 665.62 | 3,016.08 | 1,992.14 | 1.15 | 4.61 | 17.65 | -- | 25.46 | 22.42 | 33.83 | 30.42 | 45.44 | 44.70 | 22.07 | 18.83 | 2.76 | 141.98 | 0.0444 | 55.91 | 9.58 | 9.38 | 17.75 | 18.99 | 27.31 | 34.73 |
| Lupin Ltd | 227.08bn | 32.82bn | 893.26bn | 21.87k | 27.27 | 5.19 | 19.96 | 3.93 | 71.72 | 71.72 | 496.28 | 376.80 | 0.8537 | 1.28 | 4.46 | -- | 12.43 | 4.53 | 18.59 | 7.16 | 69.87 | 60.88 | 14.56 | 5.95 | 1.26 | 14.13 | 0.2396 | 29.56 | 13.48 | 8.11 | 71.41 | -- | 20.11 | 14.87 |
| Zydus Lifesciences Ltd | 232.42bn | 45.26bn | 988.88bn | 27.92k | 21.85 | 4.13 | 17.88 | 4.25 | 44.97 | 44.97 | 230.98 | 238.05 | 0.6992 | 1.65 | 5.01 | 8,325,214.00 | 13.88 | 10.92 | 19.46 | 16.35 | 72.73 | 63.12 | 19.86 | 16.73 | 1.43 | 2,391.72 | 0.1087 | 17.81 | 18.90 | 10.27 | 17.96 | 30.92 | 13.63 | 25.74 |
| Dr Reddy's Laboratories Ltd | 326.44bn | 56.55bn | 1.05tn | 26.94k | 18.63 | 3.13 | 14.15 | 3.22 | 67.81 | 67.81 | 391.46 | 403.24 | 0.7395 | 1.48 | 3.82 | 12,115,460.00 | 12.97 | 12.15 | 17.54 | 16.94 | 69.43 | 66.18 | 17.54 | 15.81 | 1.37 | 26.74 | 0.1211 | 14.69 | 16.54 | 13.26 | 1.38 | 22.84 | 41.26 | 9.86 |
| Mankind Pharma Ltd | 122.07bn | 19.86bn | 1.09tn | 27.00k | 53.68 | 7.60 | 41.45 | 8.92 | 49.17 | 49.27 | 301.68 | 347.39 | 0.6146 | 1.86 | 10.23 | 4,521,274.00 | 10.10 | 14.93 | 12.74 | 19.39 | 71.42 | 67.59 | 16.44 | 17.70 | 0.8524 | 5.75 | 0.3688 | 0.00 | 18.98 | 15.79 | 3.90 | 14.03 | 18.41 | -- |
| Torrent Pharmaceuticals Ltd | 115.16bn | 19.11bn | 1.19tn | 16.11k | 62.06 | 15.63 | 43.83 | 10.30 | 56.47 | 56.47 | 340.25 | 224.28 | 0.7665 | 1.15 | 6.21 | 7,149,743.00 | 12.72 | 9.54 | 19.20 | 14.72 | 75.90 | 72.56 | 16.60 | 14.14 | 0.6532 | 11.60 | 0.2967 | 61.09 | 7.35 | 7.72 | 15.39 | 14.48 | 8.51 | 30.36 |
| Cipla Ltd | 275.48bn | 52.73bn | 1.20tn | 30.31k | 22.72 | 3.84 | 19.05 | 4.35 | 65.24 | 65.24 | 340.86 | 386.24 | 0.7859 | 1.64 | 5.36 | 9,087,725.00 | 15.09 | 11.89 | 17.88 | 14.49 | 67.59 | 59.55 | 19.21 | 14.74 | 3.22 | 97.10 | 0.0138 | 22.40 | 6.88 | 9.97 | 27.93 | 27.80 | 9.14 | 34.08 |
Data as of Jul 18 2025. Currency figures normalised to Lupin Ltd's reporting currency: Indian Rupee INR
20.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Jun 2025 | 16.37m | 3.59% |
| ICICI Prudential Asset Management Co. Ltd.as of 31 May 2025 | 14.04m | 3.07% |
| Life Insurance Corporation of India (Investment Portfolio)as of 31 Dec 2024 | 10.36m | 2.27% |
| The Vanguard Group, Inc.as of 02 Jul 2025 | 9.02m | 1.98% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 May 2025 | 8.19m | 1.79% |
| SBI Funds Management Ltd.as of 30 Jun 2025 | 7.80m | 1.71% |
| HDFC Life Insurance Co. Ltd. (Investment Portfolio)as of 30 Jun 2025 | 7.37m | 1.61% |
| Mirae Asset Investment Managers (India) Pvt Ltd.as of 30 Jun 2025 | 7.18m | 1.57% |
| BlackRock Fund Advisorsas of 03 Jul 2025 | 6.25m | 1.37% |
| Axis Asset Management Co. Ltd.as of 30 Jun 2025 | 6.00m | 1.31% |
More ▼
Data from 31 Mar 2025 - 10 Jul 2025Source: FactSet Research Systems Inc.
